Patents by Inventor Robert A. Floyd

Robert A. Floyd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10555915
    Abstract: The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC). Preferably, the compositions for treating AAT will be administered orally. However, other methods which deliver the compositions for treating AAT systemically to the body should work equally well.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: February 11, 2020
    Assignees: Hough Ear Institute, Oklahoma Medical Research Foundation
    Inventors: Richard Dana Kopke, Robert A. Floyd
  • Patent number: 10398659
    Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: September 3, 2019
    Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventors: Rheal A. Towner, Robert A. Floyd
  • Patent number: 10111843
    Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: October 30, 2018
    Assignees: Hough Ear Institute, Oklahoma Medical Research Foundation
    Inventors: Richard D. Kopke, Robert A. Floyd, Rheal Towner
  • Publication number: 20180228744
    Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.
    Type: Application
    Filed: April 12, 2018
    Publication date: August 16, 2018
    Inventors: Rheal A. TOWNER, Robert A. FLOYD
  • Patent number: 10022346
    Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: July 17, 2018
    Assignees: Hough Ear Institute, Oklahoma Medical Research Foundation
    Inventors: Richard D. Kopke, Robert A. Floyd, Rheal Towner
  • Patent number: 9968569
    Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: May 15, 2018
    Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventors: Rheal A. Towner, Robert A. Floyd
  • Publication number: 20170281583
    Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
    Type: Application
    Filed: June 23, 2017
    Publication date: October 5, 2017
    Applicants: HOUGH EAR INSTITUTE, OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventors: Richard D. KOPKE, Robert A. FLOYD, Rheal TOWNER
  • Publication number: 20170224635
    Abstract: The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC). Preferably, the compositions for treating AAT will be administered orally. However, other methods which deliver the compositions for treating AAT systemically to the body should work equally well.
    Type: Application
    Filed: April 24, 2017
    Publication date: August 10, 2017
    Applicants: Hough Ear Institute, OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventors: Richard D. Kopke, Robert A. Floyd
  • Publication number: 20170202797
    Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
    Type: Application
    Filed: January 27, 2017
    Publication date: July 20, 2017
    Applicants: HOUGH EAR INSTITUTE, OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventors: Richard D. KOPKE, Robert A. FLOYD, Rheal TOWNER
  • Patent number: 9642823
    Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: May 9, 2017
    Assignees: Hough Ear Institute, Oklahoma Medical Research Foundation
    Inventors: Richard D. Kopke, Robert A. Floyd, Rheal Towner
  • Publication number: 20170027891
    Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.
    Type: Application
    Filed: October 13, 2016
    Publication date: February 2, 2017
    Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventors: Rheal A. TOWNER, Robert A. FLOYD
  • Patent number: 9474748
    Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: October 25, 2016
    Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventors: Rheal A. Towner, Robert A. Floyd
  • Publication number: 20160158173
    Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
    Type: Application
    Filed: February 18, 2016
    Publication date: June 9, 2016
    Applicants: HOUGH EAR INSTITUTE, OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventors: Richard D. KOPKE, Robert A. FLOYD, Rheal TOWNER
  • Patent number: 9289404
    Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprises 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: March 22, 2016
    Assignees: HOUGH EAR INSTITUTE, OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventors: Richard D. Kopke, Robert A. Floyd, Rheal Towner
  • Publication number: 20150376251
    Abstract: A method is described for inducing formation of neurons from embryonal stem cells, by utilizing an exogenous ferritin-H inducer.
    Type: Application
    Filed: March 2, 2015
    Publication date: December 31, 2015
    Inventors: Robert H. Broyles, Robert A. Floyd, Austin C. Roth, Visar Belegu
  • Publication number: 20140200234
    Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.
    Type: Application
    Filed: January 21, 2014
    Publication date: July 17, 2014
    Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventors: Rheal A. TOWNER, Robert A. FLOYD
  • Publication number: 20140187631
    Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprises 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
    Type: Application
    Filed: February 3, 2012
    Publication date: July 3, 2014
    Inventors: Richard D. Kpoke, Robert A. Floyd, Rheal Towner
  • Patent number: 8633249
    Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: January 21, 2014
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Rheal A. Towner, Robert A. Floyd
  • Publication number: 20130225694
    Abstract: Nitrone-based compositions are disclosed that may be utilized for the prevention and treatment of a variety of ophthalmic diseases or conditions where RPE65 protein isomerohydrolase is implicated. Methods of production and use of said nitrone-based compositions, as well as pharmaceutical and ophthalmic compositions containing same, are disclosed.
    Type: Application
    Filed: February 25, 2013
    Publication date: August 29, 2013
    Applicants: Oklahoma Medical Research Foundation, The Board of Regents of the University of Oklahoma
    Inventors: Robert E. Anderson, Nawajes A. Mandal, Jian-Xing Ma, Gennadiy Moiseyev, Robert A. Floyd
  • Patent number: 8420595
    Abstract: The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition includes compounds which function as free radical traps such as phenyl butyl nitrone (PBN), free radical scavengers, such as edaravone, resveratrol, ebselen and iron chelator and compounds from the family of antioxidant compounds including, but not limited to, N-acetylcysteine (NAC), Acetyl-L-Carnitine (ALCAR), glutathione monoethylester, ebselen, D-methionine and carbamathione. The compositions of the current invention may be delivered by injections or orally.
    Type: Grant
    Filed: July 25, 2007
    Date of Patent: April 16, 2013
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Richard Dana Kopke, Robert A. Floyd